Company intelligence / Profile preview

StraxCorp

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

FDA granted Breakthrough Device Designation to OssView software for measuring bone microstructural deterioration and fracture risk; 510(k) submission filed February 2023, targeting clearance in FY2024; pro-forma revenue $11.5m FY2023 (up 55% YoY).

Therapeutic areas: EndocrinologyRheumatologyOther
Modalities: Software as a Service (SaaS)Cone Beam CT ImagingAI/Deep Learning AI
Industry: Medical Imaging

Partnerships

Stryker (Distribution Agreement for HiRise)Stryker Device Packaging Program

Beyond the preview

Go deeper on StraxCorp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StraxCorp.

Explore the full profile